Skip to main content
. 2021 Nov 29;2021(11):CD013531. doi: 10.1002/14651858.CD013531.pub2

Summary of findings 8. 100 mg olorinab 3 times/day compared to 25 mg olorinab 3 times/day for the management of abdominal pain in Crohn's disease and inflammatory bowel disease.

100 mg olorinab 3 times/day compared to 25 mg olorinab 3 times/day for the management of abdominal pain in Crohn's disease and inflammatory bowel disease
Patient or population: people with Crohn's disease
Setting: unstated (multicentre, USA)
Intervention: 100 mg olorinab 3 times/day
Comparison: 25 mg olorinab 3 times/day
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI) № of participants
(studies) Certainty of the evidence
(GRADE)
Risk with 25 mg olorinab 3 times/day Risk with 100 mg olorinab 3 times/day
Treatment success as defined by the authors Not measured
Pain frequency or change in pain frequency Not measured
Pain intensity (30% reduction in weekly AAPS) Study population RR 0.66
(0.38 to 1.15) 14
(1 study) ⊕⊝⊝⊝
very low a b
1000 per 1000 660 per 1000
(380 to 1000)
Withdrawal due to adverse events 0 per 1000 0 per 1000
(0 to 0) Not estimable 14
(1 study) ⊕⊝⊝⊝
very low a b
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidenceHigh certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

aDowngraded one level due to risk of bias.
bDowngraded two levels due to imprecision from very sparse data.